# Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

> **NCT06522373** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** MT-0169

## Key facts

- **NCT ID:** NCT06522373
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-10-21
- **Primary completion:** 2024-10-21
- **Final completion:** 2024-10-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Request
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06522373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06522373, "Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06522373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*